Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy

Abhisek Swaika, William A. Hammond, Richard W Joseph

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. The net result of this targeted approach is decreased toxicity and increased efficacy of immunotherapy. More specifically, therapies that inhibit the interaction between programmed death ligand 1 (PD-L1), present on the surface of tumor or antigen-presenting cells, and programmed death 1 (PD-1), present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally considered to be immunogenic. Herein, we review the current landscape of anti-PD-1 and anti-PD-L1 therapies in the world of oncology. We have performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, the ClinicalTrials.gov registry, and abstracts from major oncology meetings in order to summarize the clinical data of anti-PD-1/PD-L1 therapies.

Original languageEnglish (US)
Pages (from-to)4-17
Number of pages14
JournalMolecular Immunology
Volume67
Issue number2
DOIs
StatePublished - Oct 1 2015

Fingerprint

Ligands
Neoplasms
Immunotherapy
Immune System
Therapeutics
Neoplasm Antigens
Antigen-Presenting Cells
PubMed
Registries
Cell Death
Lymphocytes

Keywords

  • Cancer
  • Immune evasion
  • Immunotherapy
  • PD-1
  • PD-L1

ASJC Scopus subject areas

  • Molecular Biology
  • Immunology

Cite this

Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. / Swaika, Abhisek; Hammond, William A.; Joseph, Richard W.

In: Molecular Immunology, Vol. 67, No. 2, 01.10.2015, p. 4-17.

Research output: Contribution to journalArticle

Swaika, Abhisek ; Hammond, William A. ; Joseph, Richard W. / Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. In: Molecular Immunology. 2015 ; Vol. 67, No. 2. pp. 4-17.
@article{58904a854f2f4758802a514331217e60,
title = "Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy",
abstract = "Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. The net result of this targeted approach is decreased toxicity and increased efficacy of immunotherapy. More specifically, therapies that inhibit the interaction between programmed death ligand 1 (PD-L1), present on the surface of tumor or antigen-presenting cells, and programmed death 1 (PD-1), present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally considered to be immunogenic. Herein, we review the current landscape of anti-PD-1 and anti-PD-L1 therapies in the world of oncology. We have performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, the ClinicalTrials.gov registry, and abstracts from major oncology meetings in order to summarize the clinical data of anti-PD-1/PD-L1 therapies.",
keywords = "Cancer, Immune evasion, Immunotherapy, PD-1, PD-L1",
author = "Abhisek Swaika and Hammond, {William A.} and Joseph, {Richard W}",
year = "2015",
month = "10",
day = "1",
doi = "10.1016/j.molimm.2015.02.009",
language = "English (US)",
volume = "67",
pages = "4--17",
journal = "Molecular Immunology",
issn = "0161-5890",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy

AU - Swaika, Abhisek

AU - Hammond, William A.

AU - Joseph, Richard W

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. The net result of this targeted approach is decreased toxicity and increased efficacy of immunotherapy. More specifically, therapies that inhibit the interaction between programmed death ligand 1 (PD-L1), present on the surface of tumor or antigen-presenting cells, and programmed death 1 (PD-1), present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally considered to be immunogenic. Herein, we review the current landscape of anti-PD-1 and anti-PD-L1 therapies in the world of oncology. We have performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, the ClinicalTrials.gov registry, and abstracts from major oncology meetings in order to summarize the clinical data of anti-PD-1/PD-L1 therapies.

AB - Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. The net result of this targeted approach is decreased toxicity and increased efficacy of immunotherapy. More specifically, therapies that inhibit the interaction between programmed death ligand 1 (PD-L1), present on the surface of tumor or antigen-presenting cells, and programmed death 1 (PD-1), present on the surface of activated lymphocytes, are generating much excitement and enthusiasm, even in malignancies that are not traditionally considered to be immunogenic. Herein, we review the current landscape of anti-PD-1 and anti-PD-L1 therapies in the world of oncology. We have performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, the ClinicalTrials.gov registry, and abstracts from major oncology meetings in order to summarize the clinical data of anti-PD-1/PD-L1 therapies.

KW - Cancer

KW - Immune evasion

KW - Immunotherapy

KW - PD-1

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=84930730522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930730522&partnerID=8YFLogxK

U2 - 10.1016/j.molimm.2015.02.009

DO - 10.1016/j.molimm.2015.02.009

M3 - Article

VL - 67

SP - 4

EP - 17

JO - Molecular Immunology

JF - Molecular Immunology

SN - 0161-5890

IS - 2

ER -